6 results
6-K
EX-99.1
NLSP
NLS Pharmaceutics Ltd
29 Dec 23
Report of Foreign Private Issuer
4:30pm
Mazindol ER versus placebo in adult patients with narcolepsy. Along with IRB approval and the green light from the FDA, NLS has retained a contract
6-K
EX-99.1
NLSP
NLS Pharmaceutics Ltd
30 Aug 23
Report of Foreign Private Issuer
5:25pm
Sleepiness Scale (ESS).
Along with IRB approval and the green light from the FDA, NLS has retained a contract research organization (CRO) and has enrolled
6-K
EX-99.1
NLSP
NLS Pharmaceutics Ltd
2 May 23
Report of Foreign Private Issuer
8:30am
Exhibit 99.1
NLS Pharmaceutics Receives Green Light from the U.S. FDA to Proceed with Phase 3 Clinical Program (AMAZE) for Quilience® (Mazindol ER
6-K
NLSP
NLS Pharmaceutics Ltd
2 May 23
Report of Foreign Private Issuer
8:30am
Pharmaceutics Ltd., or the Registrant, issued a press release titled: “NLS Pharmaceutics Receives Green Light from the U.S. FDA to Proceed with Phase 3 Clinical … subsequently filed or furnished.
EXHIBIT INDEX
Exhibit
Number
Description of Document
Press release titled: “NLS Pharmaceutics Receives Green Light from
- Prev
- 1
- Next